Type I Interferon-Driven Monocyte Dysregulation and MAS-associated CD8 + T cells During Macrophage Activation Syndrome
Preprint
Abstract
Macrophage activation syndrome (MAS) is driven by a hyperinflammatory response characterized by aberrant activation of lymphocytes and phagocytes. While monocytes and macrophages are thought to be important in MAS pathogenesis, their role remains poorly understood. We used bulk and single-cell RNA sequencing (RNA-Seq) on sorted monocytes from children with MAS and healthy controls to identify transcriptional changes during MAS. We defined a MAS signature in classical monocytes that correlated with ferritin and was elevated in monocytes from systemic lupus erythematosus and COVID-19 patients. We also identified a subset of classical monocytes with high levels of interferon-stimulated genes (ISGs) that expanded during MAS. Surprisingly, the transcriptional signature of these cells was driven by type I IFNs, rather than IFNγ. Consistent with this finding, we detected increased levels of circulating IFNβ during MAS, suggesting that IFNβ plays an unrecognized role in driving MAS monocyte responses. We also identified a MAS-associated CD8 + T cell population with a distinctive transcriptional signature. We used cell-cell communication algorithms to predict increased immunoregulatory interactions between monocytes and T cells during MAS. Together, these results provide new evidence for a role for type I IFN during MAS and identify a unique CD8 + T cell population that may contribute to MAS pathophysiology.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K08 AI170918)
- National Institute of Allergy and Infectious Diseases (R01 AI150178-01S1)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR076242)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32 AR007108)
- Rheumatology Research Foundation
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32 HD007233)
- National Heart, Lung, and Blood Institute (F32 HL156516)
This publication has 63 references indexed in Scilit:
- Type I Interferon Signature is Associated With Lung Disease, Drug‐Associated Immune Reactions, and Genetic Variation in Interferon‐Linked Pathways in Still DiseaseArthritis & Rheumatology, 2026
- Automatic cell-type harmonization and integration across Human Cell Atlas datasetsCell, 2023
- Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic ArthritisACR Open Rheumatology, 2019
- Macrophage Activation Syndrome2018
- Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic ArthritisArthritis Care & Research, 2017
- Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 PatientsArthritis & Rheumatology, 2014
- The myeloid‐related proteins 8 and 14 complex, a novel ligand of toll‐like receptor 4, and interleukin‐1β form a positive feedback mechanism in systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2009
- Gene expression profiling of peripheral blood from patients with untreated new‐onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndromeArthritis & Rheumatism, 2007
- A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonistsArthritis & Rheumatism, 2007
- The diagnostic significance of soluble CD163 and soluble interleukin‐2 receptor α‐chain in macrophage activation syndrome and untreated new‐onset systemic juvenile idiopathic arthritisArthritis & Rheumatism, 2007